Post# 599798 of 600033 dmb2, are you completely ruling out the possibility of the regulatory authorities approving DCVax-L on a tissue agnostic basis now, because of: (1) its non-toxic and excellent safety record. As of result, it will not harm cancer patients, but it probably will benefit most cancer patients; (2) it’s mechanism of action (MOA) of using the patient’s own dendritic cells, pulsed with the patient’s own tumor lysate (regardless of which organ(s) the tumor(s) is/are located), to activate T Cells to find, destroy and continue to fight the cancer tumor(s). This MOA is not just specific to the brain, but should work for every organ in the human body.
Then, require NWBio to complete post-approval Phase IV, confirmatory basket trials to validate the efficacy results, and to keep the tissue-agnostic approvals?
SALIENT INSIGHT # 2:
Bright Boy
Re: SkyLimit2022 post# 599901
Thursday, June 08, 2023 5:54:09 PM
Post# 599910 of 600034 To dovetail into your post:
Bright Boy
Re: attilathehunt post# 599819
Thursday, June 08, 2023 2:42:24 PM
Post# 599831 of 599870 So I'm going to go out on a limb here in my following comments, but I believe it's time and I believe the scientific/medical community is coming around to believe that Northwest and it's brilliant team from Alton Boynton, Linda Powers, Dr. Bosch, Allen Turner( former NWBO employee), Dr. Linda Liau and her UCLA team, my friend that is truly a legend in the biotech world and everyone else involved in the development/discovery and understanding of the technology that drives the process that is DCVax-L which provides the world of medicine the ability to DIRECT THE IMMUNE SYSTEM and thereby TARGET ALL DISEASES !!!!!!! In simple terms, DCVax-L is able to identify antigens, which in a perfect system, ARE NOT SUPPOSED TO BE THERE !!!! AND GET RID OF THEM!!!!!!!
AND Yes!!! You already know what this means !!! DCVax-L represents the platform technology that is a general application for all diseases !!!!!
"...the most appropriate method for identifying truly relevant tumor-associated antigenic peptides is to analyze those actually presented by the MHC-I molecules on tumor cells...Analysis of the peptide repertoire associated with the MHC-I molecules of cancer cells...provides a… pic.twitter.com/EpB03Ccl7V
"The analytical challenge lies in the discrimination between the tumor-related peptides among a majority of nondisease-related peptides that are presented on the cell surface. This could be overcome by cancer specific database search of the identified peptides to select those… pic.twitter.com/dINn7CpQ5u
Nov ’02: DCVax-L (“L”) FDA orphan status Dec ’06: L P3 starts Nov ’07: L EU orphan status Oct ’10: Poly-ICLC + L combo starts. Interim data img 1 Jan ’20: Keytruda + L combo starts. Interim data img 2 Sep ’20: Flaskworks acquired Oct ’20: L data lock Oct ’21: UK Human… pic.twitter.com/FM77cfBCDQ
— Gregory Zivic, MD (@metacollectiveG) June 5, 2023
Gregory Zivic, MD 4,274 Tweets See new Tweets Gregory Zivic, MD @metacollectiveG Follows you Artist/Emergency Physician/Manufacturing Engineer/Investor in NWBO Co-owner META Collective Media, Sailor, Captain SV Catsulo. Not an investment advisor. At all ArtistUnited Statesfineartamerica.com/profiles/grego…Joined December 2015 735 Following 1,546 Followers Followed by Bio99, Steven, and 139 others you follow Tweets Replies Media Likes Gregory Zivic, MD’s Tweets Gregory Zivic, MD @metacollectiveG · Jun 4 $NWBO next up; external controls. The controversy with this is hyperbole. The FDA is not going to ignore reality because those who stand to lose (be it BP or clinical researchers going down the wrong rabbit hole) are yelping. The safety is beyond compare and this is quite simple: Gregory Zivic, MD @metacollectiveG · Jun 4 $NWBO removing trials that some might believe add to bias based on patient characteristics had no effect on the analysis. Jealous researchers/BP don’t share IPD. Co. asked for IPD on all these studies. All refused. One of the Physicians lied to me directly saying he wasn’t asked. Gregory Zivic, MD @metacollectiveG · Jun 4 1/2 $NWBO Dr. Bosch’s presentation was a quiet K-Boom! In my opinion regarding T cell recruitment, activation, etc. But in particular one needs to comprehend T cell exhaustion in Cancers and in chronic viral infections (age and kill us). The clonal expansion found with DCVax Gregory Zivic, MD @metacollectiveG · Jun 4 $NWBO The “newly expanded” T cell clones I find particularly interesting. T Cell dysfunction and exhaustion cannot be overcome by PD-1 inhibition or Car-T (Car T cells themselves become exhausted and why this therapy has it’s drawbacks) Gregory Zivic, MD @metacollectiveG · Jun 4 2/2 $NWBO Also important was the finding that other Cancer antigens not previously found in GBM were found in the DCs after pulsing with Lysate. Also, viral antigens present. None of these have formally been found on GBM tumors before. Gregory Zivic, MD @metacollectiveG · Jun 4 $NWBO If anyone’s incapable of comprehending this take away one thing; what’s being shown here is the pivot toward how ALL disease will be treated and cured; all solid tumors, blood cancers, autoimmunity, viruses… incredible. Brilliance. https://nwbio.com/wp-content/uploads/NWBT_ASCO_slides_06032022_FINAL.pdf
Market Data 
Markets 
AI
